EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pulmonary fibrosis: pathogenesis and therapeutic strategies

Jianhai Wang iD, Kuan Li, De Hao, Xue Li, Yu Zhu, Hongzhi Yu, Huaiyong Chen

MedComm · 2024-10 · 5 (10)

DOI: 10.1002/mco2.744 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 23.09.2024. Verfasst von Jianhai Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine Haihe Hospital Tianjin University Tianjin China. Die Arbeit wurde bisher 121-mal zitiert (Crossref) und nennt 255 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Tianjin Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary fibrosis (PF) is a chronic and progressive lung disease characterized by extensive alterations of cellular fate and function and excessive accumulation of extracellular matrix, leading to lung tissue scarring and impaired respiratory function. Although our understanding of its pathogenesis has increased, effective treatments remain scarce, and fibrotic progression is a major cause of mortality. Recent research has identified various etiological factors, including genetic predispositions, environmental exposures, and lifestyle factors, which contribute to the onset and progression of PF. Nonetheless, the precise mechanisms by which these factors interact to drive fibrosis are not yet fully elucidated. This review thoroughly examines the diverse etiological factors, cellular and molecular mechanisms, and key signaling pathways involved in PF, such as TGF‐β, WNT/β‐catenin, and PI3K/Akt/mTOR. It also discusses current therapeutic strategies, including antifibrotic agents like pirfenidone and nintedanib, and explores emerging treatments targeting fibrosis and cellular senescence. Emphasizing the need for omni‐target approaches to overcome the limitations of current therapies, this review integrates recent findings to enhance our understanding of PF and contribute to the development of more effective prevention and management strategies, ultimately improving patient outcomes.

Schlagwörter

Stichwörter der Autor:innen

biomarkersendotheliumepitheliumimmune cellsmicrobiome

Autor:innen und Institutionen

  • Department of Respiratory Medicine Haihe Hospital Tianjin University Tianjin China.
  • Department of Tuberculosis Haihe Hospital Tianjin University Tianjin China.
  • Key Research Laboratory for Infectious Disease Prevention for State Administration of Traditional Chinese Medicine Tianjin Institute of Respiratory Diseases Tianjin China.
  • Tianjin Key Laboratory of Lung Regenerative Medicine, Haihe Hospital Tianjin University Tianjin China.
  • Department of Clinical Laboratory Nankai University Affiliated Third Central Hospital Tianjin China.
  • Department of Clinical Laboratory The Third Central Hospital of Tianjin Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases Artificial Cell Engineering Technology Research Center of Tianjin Tianj…

ORCID-Profile: Jianhai Wang

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Tianjin Municipality

Zitieren

APA

Wang, J., Li, K., Hao, Li, X., Zhu, Y., Yu, H., & Chen, H. (2024). Pulmonary fibrosis: pathogenesis and therapeutic strategies. MedComm, 5(10). https://doi.org/10.1002/mco2.744

Vancouver

Wang J, Li K, Hao, Li X, Zhu Y, Yu H, et al. Pulmonary fibrosis: pathogenesis and therapeutic strategies. MedComm. 2024;5(10). doi:10.1002/mco2.744

BibTeX
@article{Wang2024,
  author = {Wang, Jianhai and Li, Kuan and Hao, De and Li, Xue and Zhu, Yu and Yu, Hongzhi and Chen, Huaiyong},
  title = {Pulmonary fibrosis: pathogenesis and therapeutic strategies},
  journal = {MedComm},
  year = {2024},
  volume = {5},
  number = {10},
  doi = {10.1002/mco2.744}
}
Kostenlos starten →